Immunohistochemistry Market by Product Type (Antibodies, Reagents, Equipment, and Kits), Application (Diagnostic Applications, Research Applications, and Forensic Applications), End User (Hospitals & Diagnostic Laboratories, Academic & Research Institutes, and Other End Users): Global Market Size Estimates and Forecast (2022-2030)

Code: BMIRE00027047 | Pages: 100 | Industry: Biotechnology | Date: Oct 2022 | Type: Global

The market crossed US$ 2.31 billion mark in 2022 and is expected to hit US$ 4.24 billion by 2030, recording a CAGR of 7.90% during the forecast period.

Immunohistochemistry has been significantly growing with the high adoption of machine learning.

Moreover, increasing implementation of automation and machine learning in IHC solutions, expected to significantly drive the market over the forecast period, are some of the major factors driving the market growth. Further, advancements in IHC protocols have enhanced its demand to a significant level in disease diagnosis. In addition, the increase in product approvals and the launch of advanced IHC systems for diagnosis of several disease are further propelling the market growth. The antibodies segment is expected to owing to the vital usage of antibodies in disease diagnosis and drug testing. Further, other segment such as equipment, reagents, and kits is also expected to gain traction during the forecasted year.

Within the report, the market is segmented into product, application, end use, and geography. By product, the market is further segmented into antibodies, equipment, reagent, and kits. On the basis of application, the market is segmented into diagnostic, research, and forensic applications. By end user, the market is categorized into hospital & diagnostic laboratories, academic & research institutes, and other end users. Geographically, the market is subsegmented into North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa.

Multiplexed IHC is a far-re

Get more information on this report :

aching technology that empowered the growth of futuristic innovations.

Multiplexed IHC helps address the technical challenges associated with the labeled fluorescence detection-based method, thereby spurring market growth. The rising geriatric population in developed and emerging nations would favorably influence the immunohistochemistry market. The incidence of age-related disorders is expected to rise intensely as the geriatric population is growing significantly. RT-PCR, IHC, and an electron microscope were for the detection of virus, indicating that the effect of SARS-CoV-2 is not restricted to the lungs. For instance, in March 2021, Roche introduced the DISCOVERY Green HRP kit for the detection and profiling of cell populations and biomarkers in tissue-based research. This kit can be utilized in combination with other detection kits, expanding the multiplexing capacity of in situ hybridization and IHC. The immunohistochemistry technology is limited to single parametric evaluations of a sample.

Rising adoption in various end users is one of the major factors accelerating the market growth.

The hospitals and diagnostic laboratories segment dominates the market and accounted for the largest share of more than 70.5% of the overall revenue. The growth was attributed to the high volume of IHC tests carried out in the hospitals settings. Furthermore, with the constant changes in healthcare industry, the need for hospitals with advanced facilities has also increased. This, in turn, is also anticipated to propel the revenue generation in this market segment. Other end users such as academic & research institutes, and other end user such as CROs, pharma & biopharma companies, and forensic laboratories are also encouraging the use of this display technology.

Recent strategic developments in immunohistochemistry market

The immunohistochemistry market has undergone several significant developments, and a few of these have been mentioned below:

  • In August 2021, Roche received FDA approval for VENTANA MMR RxDx companion diagnostic test based on immunohistochemistry for solid tumors that are deficient in the MMR pathway. The test identifies patients eligible for GSK’s anti-PD1 immunotherapy, JEMPERLI.
  • In August 2021, Agilent received a CE-IVD mark in Europe for its PD-L1 IHC 22C3 pharmDx assay for the identification of oesophageal cancer patients for treatment with KEYTRUDA.
  • In January 2021, Biocare medical LLC launched the ONCORE Pro, a fully automated in-vitro diagnostic benchtop system for In-situ Hybridization (ISH) and IHC applications.

The immunohistochemistry market is driven by several players by implementing strategic activities such as investments, new launches, mergers & acquisitions, and partnerships. Thermo Fisher Scientific Inc., Merck KGaA, Danaher Corporation, PerkinelmerInc., Bio-Rad Laboratories, Inc., Cell Signaling Technology, Inc., F.Hoffmann-La Roche Ltd., Bio SB, Agilent Technologies, Inc., Abcam plc.,  are among the prominent players operating in the market.

Target audience for the report:

  • Raw material providers
  • Kits and reagents providers
  • Equipment and Reagents providers
  • Kits and Equipment service providers
  • Equipment associations, organizations, forums, and alliances
  • Government bodies, such as regulating authorities and policy makers
  • Venture capitalists, private equity firms, and start-up companies
  • Kits and reagents suppliers
  • Reagents and kits distributors and sales firms
  • End users of kits and reagents
  • Research institutes, organizations, and consulting companies

Scope of the report:

In this report, the market has been segmented on the basis of:

  • Product:
    • Antibodies
    • Reagents
    • Equipment
    • Kits
  • Application:
    • Diagnostic Application
    • Research Application
    • Forensic Application
  • End User:
    • Hospitals & Diagnostic Laboratories
    • Academic & Research Institutes
    • Other End Users (CROs, pharma & biopharma companies, and forensic laboratories)
  • Region
    • North America
    • Europe
    • Asia Pacific (APAC)
    • South & Central America
    • Middle East & Africa
  • Companies profiled
    • Thermo Fisher Scientific Inc.
    • F. Hoffmann-La Roche Ltd.
    • Merck KGaA
    • Danaher Corporation
    • Perkinelmer, Inc.
    • Bio-Rad Laboratories, Inc
    • Cell Signaling Technology, Inc.
    • Bio SB
    • Agilent Technologies, Inc.
    • Abcam plc.

The List of Companies
- Thermo Fisher Scientific Inc.
- F. Hoffmann-La Roche Ltd.
- Merck KGaA
- Danaher Corporation
- Perkinelmer, Inc.
- Bio-Rad Laboratories, Inc
- Cell Signaling Technology, Inc.
- Bio SB
- Agilent Technologies, Inc.
- Abcam plc.

Report Code
Full Name
Country Name
Email Id
Phone Number
Job Title
Company
Requirement

Note : Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.


Purchase Options
Single User License
$1500
Site License
$2500
Enterprise License
$3500